I believe that the acquisition offer will not come from these mentioned competitors.
On the diagnostics side, the most natural bidder is, of course, Brainlab, which owns warrants after already subscribing to 13% of Nexstim.
Brainlab itself also has major competitors who would certainly be interested in Nexstim’s solution as part of their own offering. For example, Stryker Group’s market cap is $148 billion, and last year they made a profit of $3.25 billion.
Buyers on the therapy side will likely start appearing more as Sinaptica’s studies progress. Potential buyers include all of those that Sinaptica has mentioned as possible acquirers in its pitch decks. As an example, let’s highlight Boston Scientific, which has a market cap of $113 billion and generated a profit of $2.9 billion last year.